跳至主要内容
临床试验/NCT04469504
NCT04469504终止不适用

Prehabilitaion Program for Sarcopenic Patients Prior to Pancreaticoduodenectomy for Periampullary Malignant Tumors

University Hospital, Lille1 个研究点 分布在 1 个国家目标入组 6 人开始时间: 2022年5月17日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
终止
发起方
入组人数
6
试验地点
1
主要终点
Post-operative severe pancreatic fistula (Grade B and C)

研究概览

简要总结

Major digestive surgery is associated with a significant rate of postoperative complications. To improve postoperative outcome, efforts are focused on postoperative course leading to the concept of rehabilitation. However, the rehabilitation concept does not allow to improve muscular and functional reserves at the time of surgery. Sarcopenia is a condition characterized by loss of skeletal muscle mass and function. Also, the prevalence of sarcopenia in patients with cancer is high and has a prevalence of around 25% in patients with pancreatic cancer, with a considerable impact on postoperative and survival outcomes.

The hypothesis is the preoperative management of sarcopenia by a rehabilitation program could improve patients' operative outcomes by reducing the rate of postoperative complications.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Other
盲法
Double (Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Patients undergoing pancreaticoduodenectomy for cancer
  • •Sarcopenic status

排除标准

  • •Age younger than 18 years
  • •Medical contraindications including cardiovascular disease or clinically significant vascular disease
  • •Physical inability to exercise
  • •Emergent surgery

研究组 & 干预措施

PREHAB

Experimental

干预措施: Prehabilitation program (Other)

control group

Active Comparator

干预措施: Oral Impact (Dietary Supplement)

结局指标

主要结局

Post-operative severe pancreatic fistula (Grade B and C)

时间窗: at 90 days

Pancreatic fistula as defined by the International Study Group of pancreatic Fistula (ISGPF)

次要结局

  • Rate of program completion(at 30 days)
  • Rate of Severe postoperative complications(at 90 days)
  • Overall survival(at 1 year and at 3 years)
  • Program acceptance measure by Modified ACCEPT© questionnaire(at 30 days)
  • Satisfaction questionnaire by EVAN-G(at 30 days)
  • Satisfaction questionnaire by the questionnaire for satisfaction of hospitalized (QSH-45)(at 30 days)
  • Quality of life by EORTC-QLQc30 scale(at 1 month, 3 months, 6 months and at 1 year)

研究者

发起方
University Hospital, Lille
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验